Similar articles for PMID: 28646014

Year	Number of Results
1997	1
2000	1
2009	1
2012	1
2015	4
2016	8
2017	22
2018	28
2019	29
2020	34
2021	23
2022	22
2023	5
2024	0

1

The Impact of ⁶⁸Ga-PSMA PET/CT on Management Intent in Prostate Cancer: Results of an Australian Prospective Multicenter Study.

Roach PJ, Francis R, Emmett L, Hsiao E, Kneebone A, Hruby G, Eade T, Nguyen QA, Thompson BD, Cusick T, McCarthy M, Tang C, Ho B, Stricker PD, Scott AM. Roach PJ, et al. J Nucl Med. 2018 Jan;59(1):82-88. doi: 10.2967/jnumed.117.197160. Epub 2017 Jun 23. J Nucl Med. 2018. PMID: 28646014 Free article.

2

Impact of ⁶⁸Ga-PSMA-11 PET/CT on Staging and Management of Prostate Cancer Patients in Various Clinical Settings: A Prospective Single-Center Study.

Sonni I, Eiber M, Fendler WP, Alano RM, Vangala SS, Kishan AU, Nickols N, Rettig MB, Reiter RE, Czernin J, Calais J. Sonni I, et al. J Nucl Med. 2020 Aug;61(8):1153-1160. doi: 10.2967/jnumed.119.237602. Epub 2020 Jan 10. J Nucl Med. 2020. PMID: 31924715 Free PMC article. Clinical Trial.

3

[⁶⁸Ga]PSMA PET/CT Improves Initial Staging and Management Plan of Patients with High-Risk Prostate Cancer.

Hirmas N, Al-Ibraheem A, Herrmann K, Alsharif A, Muhsin H, Khader J, Al-Daghmin A, Salah S. Hirmas N, et al. Mol Imaging Biol. 2019 Jun;21(3):574-581. doi: 10.1007/s11307-018-1278-8. Mol Imaging Biol. 2019. PMID: 30215174

4

A prospective randomized multicentre study of the impact of gallium-68 prostate-specific membrane antigen (PSMA) PET/CT imaging for staging high-risk prostate cancer prior to curative-intent surgery or radiotherapy (proPSMA study): clinical trial protocol.

Hofman MS, Murphy DG, Williams SG, Nzenza T, Herschtal A, Lourenco RA, Bailey DL, Budd R, Hicks RJ, Francis RJ, Lawrentschuk N. Hofman MS, et al. BJU Int. 2018 Nov;122(5):783-793. doi: 10.1111/bju.14374. Epub 2018 Jun 3. BJU Int. 2018. PMID: 29726071 Clinical Trial.

5

Clinical impact of ⁶⁸ Ga-prostate-specific membrane antigen (PSMA) positron emission tomography/computed tomography (PET/CT) in patients with prostate cancer with rising prostate-specific antigen after treatment with curative intent: preliminary analysis of a multidisciplinary approach.

Albisinni S, Artigas C, Aoun F, Biaou I, Grosman J, Gil T, Hawaux E, Limani K, Otte FX, Peltier A, Sideris S, Sirtaine N, Flamen P, van Velthoven R. Albisinni S, et al. BJU Int. 2017 Aug;120(2):197-203. doi: 10.1111/bju.13739. Epub 2017 Jan 4. BJU Int. 2017. PMID: 27981732

6

⁶⁸ Ga-prostate-specific membrane antigen (PSMA) PET/CT as a clinical decision-making tool in biochemically recurrent prostate cancer.

Davies A, Foo M, Gan CL, Kourambas J, Redgrave N, Donnellan S, Appu S, Williams S, Coleman A, Segelov E, Bradley J, Soo G, Ramdave S, Kwan EM, Azad AA. Davies A, et al. Asia Pac J Clin Oncol. 2022 Oct;18(5):e204-e210. doi: 10.1111/ajco.13595. Epub 2021 Jun 23. Asia Pac J Clin Oncol. 2022. PMID: 34161628

7

⁶⁸ Ga-PSMA-PET for radiation treatment planning in prostate cancer recurrences after surgery: Individualized medicine or new standard in salvage treatment.

Habl G, Sauter K, Schiller K, Dewes S, Maurer T, Eiber M, Combs SE. Habl G, et al. Prostate. 2017 Jun;77(8):920-927. doi: 10.1002/pros.23347. Epub 2017 Mar 20. Prostate. 2017. PMID: 28317152

8

Impact of ⁶⁸Ga-PSMA-11 PET/CT on the Management of Prostate Cancer Patients with Biochemical Recurrence.

Calais J, Fendler WP, Eiber M, Gartmann J, Chu FI, Nickols NG, Reiter RE, Rettig MB, Marks LS, Ahlering TE, Huynh LM, Slavik R, Gupta P, Quon A, Allen-Auerbach MS, Czernin J, Herrmann K. Calais J, et al. J Nucl Med. 2018 Mar;59(3):434-441. doi: 10.2967/jnumed.117.202945. Epub 2017 Dec 14. J Nucl Med. 2018. PMID: 29242398 Free PMC article.

9

The use of ⁶⁸ Ga-PSMA PET CT in men with biochemical recurrence after definitive treatment of acinar prostate cancer.

Meredith G, Wong D, Yaxley J, Coughlin G, Thompson L, Kua B, Gianduzzo T. Meredith G, et al. BJU Int. 2016 Oct;118 Suppl 3:49-55. doi: 10.1111/bju.13616. Epub 2016 Sep 23. BJU Int. 2016. PMID: 27659411

10

Comparison of standard and delayed imaging to improve the detection rate of [⁶⁸Ga]PSMA I&T PET/CT in patients with biochemical recurrence or prostate-specific antigen persistence after primary therapy for prostate cancer.

Schmuck S, Nordlohne S, von Klot CA, Henkenberens C, Sohns JM, Christiansen H, Wester HJ, Ross TL, Bengel FM, Derlin T. Schmuck S, et al. Eur J Nucl Med Mol Imaging. 2017 Jun;44(6):960-968. doi: 10.1007/s00259-017-3669-5. Epub 2017 Mar 9. Eur J Nucl Med Mol Imaging. 2017. PMID: 28280856

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

151 results

Results by year